



PATIENT

Sugar Pomerleau

SPECIES

Canine

BREED

Yorkshire Terrier

SEX

Female Spayed

AGE

12 years

WEIGHT

7.8lbs

INTERPRETED BY

Maggie Machen Lamy,
DVM, DACVIM
(Cardiology)

IMAGING PERFORMED BY

Karen Ebersole,
DVM, DABVP

HOSPITAL NAME

Scanvet

REFERRING VET

Dr. Perkins

INVOICE

31642

DATE

6/29/23

PRESENTING CLINICAL SIGNS

History: Recheck echo. Grade 3/6 heart murmur.

-Current medications: Metacam 1.5mg/ml 8lb dose sid or prn. Vetmedin 0.625mg BID. Benazepril 2.5mg SID. Furosemide 10mg BID. Spironolactone 6.25mg BID. Phenobarbital 16.2mg 1 tab am and 1.5tab pm.

-Pertinent previous echo findings (2/2023 MML): Moderate MR, mild to moderate LAE, mild LVE, no TR, mild to moderate AI. LA: 1.9, LV: 1.8. Recommend continue Pimobendan/ACE-I. Discontinue Lasix/Spironolactone.

ECHOCARDIOGRAM FINDINGS

2D, m-mode, color flow and doppler imaging is available. Diffuse thickening of mitral valve leaflets (anterior>posterior) with mild prolapse into the left atrial lumen. Moderate eccentric mitral regurgitation with mild left atrial dilation. Normal MR velocity. Normal LV diameter with adequate myocardial function. The tricuspid valve appears subjectively normal, without significant tricuspid regurgitation. Normal right atrial and ventricular diameter. The pulmonic and aortic valves are normal in morphology and mobility. Normal pulmonic and aortic outflow velocities. Mild to moderate aortic and no pulmonic insufficiency. No pericardial or pleural effusion noted. No cardiac tumors observed.

CARDIAC CHART

CANINE CARDIAC PARAMETERS	MR VMAX (m/s)	TR VMAX (m/s)	LA/AO (Boon method)	LA/AO (Heart Base; Swe)	FS (%)	EF (%)	EPSS (cm)
NORMAL PARAMETER	4.5-5.5	<2.7	1.3	<1.6	28-40	40-100	<0.6
PATIENT	4.7	NA	1.5	1.5	53	86	NM
CANINE CARDIAC PARAMETERS	HR (BPM)	AV VMAX (m/s)	PV MAX (m/s)	BODY WEIGHT (kg)	LA 2D short axis Base view (cm)	LVIDd Avg; 2D and m-mode short axis (cm)	LVIDs Avg; 2D and m-mode short axis (cm)
NORMAL PARAMETER	50-100	0.7-1.7	0.7-1.6	BELOW	BELOW	BELOW	BELOW
PATIENT	96	2.0	0.8	3.5	1.7	2.3	1.1
*Normal chamber parameters expressed as a mean value (SD)				3	1.27 (5.3)	2.46 (2.46)	1.36 (5.5)
BODY WEIGHT DEPENDENT PARAMETERS				5	1.40 (4.5)	2.74 (5.2)	1.60 (4.7)
<i>*Note: All measurements based upon multi-modal images and methods. An average value is reported.</i>				10	1.50 (3.8)	3.27 (3.5)	2.06 (3.1)
				15	1.83 (2.0)	3.71 (2.4)	2.43 (2.1)
				20	2.02 (1.9)	4.14 (2.2)	2.80 (2.0)
				25	2.18 (2.4)	4.48 (2.9)	3.10 (2.5)
				30	2.33 (3.3)	4.83 (3.9)	3.39 (3.4)
				35	2.48 (4.3)	5.17 (5.0)	3.69 (4.5)
				40	2.62 (5.2)	5.48 (6.1)	3.96 (5.4)
				50	2.88 (7.1)	6.07 (8.3)	4.46 (7.4)

INTERPRETATION OF THE FINDINGS & FURTHER RECOMMENDATIONS

Chronic degenerative valve disease persists with evidence of stability. Moderate mitral and trace tricuspid regurgitation are unchanged, without progressive left heart enlargement. Compared to the prior study, findings are similar to slightly improved with mild left atrial enlargement



PATIENT

Sugar Pomerleau

identified. This would suggest there is relatively low risk for complication at this time. The aortic leak appears stable, and no additional issues have developed.

SPECIES

Canine

Reasonable to continue Pimobendan and ACE-I lifelong as prescribed. As discussed previously there is no need for diuretic therapy in this patient. This is further supported by continually improving left heart dimensions. Continued assessment of progression is recommended, with a guarded prognosis (stage B2). Patient may be at risk for development of CHF, arrhythmias, and/or sudden death going forward.

BREED

Yorkshire Terrier

Omega fatty acid supplementation and mild salt restriction may also be of some long-term benefit. Monitor for development of a progressive cough, labored breathing, exercise intolerance or collapse episodes.

SEX

Female Spayed

Anesthetic risk remains mildly elevated. Cardiac protective drug choices (opioid/benzodiazepine premedication, Propofol or alfaxalone induction, iso or sevo gas) are recommended. Monitor for arrhythmias, hypotension, and hypoxia both intra and post-operatively and intervene as necessary. Judicious IV fluid rates are recommended to avoid fluid overload. Avoid heart rate stimulating drugs such as atropine unless clinically indicated.

AGE

12 years

WEIGHT

7.8lbs

PLAN

Continue Pimobendan and ACE-I as prescribed. No indication for Lasix or Spironolactone. Utilize Hydrocodone as needed.

INTERPRETED BY


Maggie Machen Lamy,
DVM, DACVIM
(Cardiology)

Recommend monitor for progression with a recheck echocardiogram in 6 months, sooner if any development of clinical signs.

IMAGING PERFORMED BY

Karen Ebersole,
DVM, DABVP

IMAGES



HOSPITAL NAME

Scanvet

REFERRING VET


Dr. Perkins

INVOICE

31642

DATE

6/29/23



PATIENT

Sugar Pomerleau

The information and recommendations provided are based on the images presented by the referring veterinarian. No evaluation can be communicated regarding pathology that was not visible in the image/video clips provided.

SPECIES

Canine

Thank you for this referral. This report was generated using transcription software, and minor dictation errors may be present. If the clinical or image interpretation does not parallel your findings or if I can be of any further assistance, please contact me.

BREED

Yorkshire Terrier

Maggie Machen Lamy, DVM
Diplomate of the American College of Veterinary Internal Medicine (Cardiology)
info@sonopath.com

SEX

Female Spayed

AGE

12 years

WEIGHT

7.8lbs

INTERPRETED BY

Maggie Machen Lamy,
DVM, DACVIM
(Cardiology)

**IMAGING
PERFORMED BY**

Karen Ebersole,
DVM, DABVP

HOSPITAL NAME

Scanvet

REFERRING VET

Dr. Perkins

INVOICE

31642

DATE

6/29/23